Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis
David A. Mix Barrington, Courtney Riedinger, Paulina Haight, Crystal Tubbs, David E. Cohn
Topics & Concepts
MedicinePembrolizumabBevacizumabCost effectivenessOncologyInternal medicineChemotherapyWillingness to payIncremental cost-effectiveness ratioCervical cancerCost-effectiveness analysisSurgeryCancerImmunotherapyRisk analysis (engineering)EconomicsMicroeconomicsEndometrial and Cervical Cancer TreatmentsColorectal and Anal CarcinomasCancer Immunotherapy and Biomarkers